Exabis Library
Welcome to the e-CCO Library!
P426: Lympocytosis in patients with inflammatory bowel disease treated with anti-TNFa agents: is it significant?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P426: Meta-analysis of endorectal advancement flap vs. ligation of the intersphincteric fistula tract for Crohn’s and cryptoglandular high perianal fistulas
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P426: Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P426: Sex and sexuality in IBD - the pediatric gastroenterologists' point of view
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P426: Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patients
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P427 A hybrid approach of handling missing data in inflammatory bowel disease (IBD) trials: results from VISIBLE 1 and VARSITY
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P427: Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P427: Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P427: Exploring phenotype and treatment of inflammatory bowel disease in the elderly
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P427: Impact of curcuma longa on clinical activity and inflammatory markers in patients with active ulcerative colitis: a double-blind randomised placebo-controlled trial
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P427: Neutrophil-to-lymphocyte ration in ulcerative colitis predicts sustained response to infliximab
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P427: One Year Follow up of Three Phase IB/IIA Clinical Trials of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulizing Crohn's Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P427: The real-life experience of vedolizumab efficacy and safety in Crohn’s disease: a prospective observational multicentre cohort study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P428 Oral mesalamine use in Crohn’s disease after implementation of the American College of Gastroenterology guidelines: a TARGET-IBD cohort study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P428: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory Crohn’s colitis: A preliminary analysis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P428: Early and Late Fecal Calprotectin Remission - Analysis of a proactive Therapeutic Drug Monitoring Treatment Protocol
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P428: Long-term outcomes of endoscopic ballon dilation for small-bowl strictures using double balloon enteroscopy in patients with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P428: Optimizing thiopurines in Crohn's disease: low dose and low 6-TGN level are effective for maintenance of remission in Asian population
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P428: Pharmacist led clinic in Inflammatory Bowel Disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P428: Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO): Utility of and cost-saving associated with the use of a rapid assay for assessing drug level
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM